Shanghai ZJ Bio-Tech Co (SHSE:688317) LT-Debt-to-Total-Asset: 0.08 (As of Mar. 2026)


SHSE:688317 Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
69 GF Score
Price ¥15.56
GF Value ¥9.93
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Shanghai ZJ Bio-Tech Co LT-Debt-to-Total-Asset?

Shanghai ZJ Bio-Tech Co SHSE:688317 +3.11% 69 LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus rates SHSE:688317 with a GF Score™ of 69/100 and a GF Value™ of ¥9.93 (Significantly Overvalued). The stock has 2 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Shanghai ZJ Bio-Tech Co's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.08.

Shanghai ZJ Bio-Tech Co's long-term debt to total assets ratio increased from Mar. 2025 (0.03) to Mar. 2026 (0.08). It may suggest that Shanghai ZJ Bio-Tech Co is progressively becoming more dependent on debt to grow their business.

Shanghai ZJ Bio-Tech Co  (SHSE:688317) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Shanghai ZJ Bio-Tech Co LT-Debt-to-Total-Asset Related Terms

Shanghai ZJ Bio-Tech Co LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Shanghai ZJ Bio-Tech Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai ZJ Bio-Tech Co LT-Debt-to-Total-Asset Chart

Shanghai ZJ Bio-Tech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.08

Shanghai ZJ Bio-Tech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.05 0.05 0.08 0.08
SHSE:688317
69GF Score
Shanghai ZJ Bio-Tech Co Ltd SHSE:688317
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai ZJ Bio-Tech Co LT-Debt-to-Total-Asset Calculation

Shanghai ZJ Bio-Tech Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )/Total Assets (A: Dec. 2025 )
=287.227/3763.8
=0.08

Shanghai ZJ Bio-Tech Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )/Total Assets (Q: Mar. 2026 )
=286.985/3706.727
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.08 mean?
Shanghai ZJ Bio-Tech Co (SHSE:688317) has a LT-Debt-to-Total-Asset of 0.08 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shanghai ZJ Bio-Tech Co and its competitors.
Is Shanghai ZJ Bio-Tech Co's LT-Debt-to-Total-Asset too high?
Shanghai ZJ Bio-Tech Co's current LT-Debt-to-Total-Asset is 0.08. Overall, Shanghai ZJ Bio-Tech Co has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai ZJ Bio-Tech Co's LT-Debt-to-Total-Asset compare to ABT and SYK?
Shanghai ZJ Bio-Tech Co's LT-Debt-to-Total-Asset of 0.08 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?
A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Shanghai ZJ Bio-Tech Co and its competitors. Shanghai ZJ Bio-Tech Co's current LT-Debt-to-Total-Asset is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai ZJ Bio-Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co (SHSE:688317) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥9.93, compared to a current price of ¥15.56 — trading 56.7% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.08. Shanghai ZJ Bio-Tech Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Shanghai ZJ Bio-Tech Co (SHSE:688317), the current LT-Debt-to-Total-Asset is 0.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai ZJ Bio-Tech Co (SHSE:688317) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai ZJ Bio-Tech Co stock appears to be overvalued. The current stock price of ¥15.56 is trading 56.7% above its estimated GF Value™ of ¥9.93. GuruFocus considers Shanghai ZJ Bio-Tech Co to be Significantly Overvalued.

Key valuation signals for SHSE:688317:

  • LT-Debt-to-Total-Asset: 0.08
  • GF Value™: ¥9.93 vs. price of ¥15.56 (56.7% above fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the SHSE:688317 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai ZJ Bio-Tech Co Business Description

Address No. 588 Xinjun Ring Road, Building 26, Pujiang Hi-Tech Park, Caohejing Development Zone, Shanghai, CHN
Shanghai ZJ Bio-Tech Co Ltd is engaged in research and development, production and sales of genetic diagnostic reagents and instruments and equipment. The rapid real-time fluorescent PCR diagnostic test reagents developed by the company are mainly used in clinical medicine, public health emergencies, entry-exit inspection and quarantine, food inspection, animal husbandry, aquaculture and other fields.
69GF Score

Get the complete analysis for SHSE:688317

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.56
Price
¥9.93
GF Value